Anti-idiotypic antibodies to BCMA-targeted binding domains and related compositions and methods
AssigneeJuno Therapeutics, Inc.
InventorsCollin Hauskins, Kimberly Harrington
Life of this patent
Estimating the term…
Abstract
Provided are anti-idiotype antibodies that specifically recognize anti-BCMA antibody moieties, in particular, anti-BC-MA antibody moieties present in recombinant receptors, including chimeric antigen receptors (CARs). The disclosure further relates to uses of antiidiotype antibodies for specifically identifying and/or selecting cells expressing such recombinant receptors, such as anti-BCMA CAR T cells. The disclosure further relates to uses of anti-idiotype antibodies for specifically activating such cells.
Claims20
An anti-idiotype antibody or antigen-binding fragment thereof that binds to an anti-BCMA target antibody or antigen-binding fragment thereof, wherein the anti-idiotype antibody or antigen-binding fragment comprises:
- (a) a VH region comprising a CDR-H1, a CDR-H2, and a CDR-H3, respectively, comprising the CDR-H1, CDR-H2, and CDR-H3 amino acid sequences contained within the amino acid sequence of SEQ ID NO:
- 114;
- and
- a VL region comprising a CDR-L1, a CDR-L2, and a CDR-L3, respectively, comprising the CDR-L1, CDR-L2, and CDR-L3 amino acid sequences contained within the amino acid sequence of SEQ ID NO:
- 115.
Dependencies are inferred from the claim text.